B-cell tolerance in transplantation: Is repertoire remodeling the answer?

Ronald F. Parsons, Kumar Vivek, Robert R. Redfield, Thi Sau Migone, Michael P. Cancro, Ali Naji, Hooman Noorchashm

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

T lymphocytes are the primary targets of immunotherapy in clinical transplantation; however, B-lymphocytes and their secreted alloantibodies are also highly detrimental to the allograft. Therefore, the achievement of sustained organ transplant survival will likely require the induction of B-lymphocyte tolerance. During development, acquisition of B-cell tolerance to self-antigens relies on clonal deletion in the early stages of B-cell compartment ontogeny. We contend that this mechanism should be recapitulated in the setting of alloantigens and organ transplantation to eliminate the alloreactive B-cell subset from the recipient. Clinically feasible targets of B-cell-directed immunotherapy, such as CD20 and B-lymphocyte stimulator (BLyS), should drive upcoming clinical trials aimed at remodeling the recipient B-cell repertoire.

Original languageEnglish (US)
Pages (from-to)703-723
Number of pages21
JournalExpert Review of Clinical Immunology
Volume5
Issue number6
DOIs
StatePublished - Nov 2009
Externally publishedYes

Fingerprint

Transplantation Tolerance
B-Lymphocytes
Immunotherapy
B-Cell Activating Factor
Clonal Deletion
B-Lymphocyte Subsets
Isoantibodies
Tissue Survival
Isoantigens
Autoantigens
Organ Transplantation
Allografts
Transplantation
Clinical Trials
T-Lymphocytes
Transplants

Keywords

  • Allograft
  • B cell
  • BLyS
  • Homeostasis
  • Rejection
  • Selection
  • Tolerance

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Parsons, R. F., Vivek, K., Redfield, R. R., Migone, T. S., Cancro, M. P., Naji, A., & Noorchashm, H. (2009). B-cell tolerance in transplantation: Is repertoire remodeling the answer? Expert Review of Clinical Immunology, 5(6), 703-723. https://doi.org/10.1586/eci.09.63

B-cell tolerance in transplantation : Is repertoire remodeling the answer? / Parsons, Ronald F.; Vivek, Kumar; Redfield, Robert R.; Migone, Thi Sau; Cancro, Michael P.; Naji, Ali; Noorchashm, Hooman.

In: Expert Review of Clinical Immunology, Vol. 5, No. 6, 11.2009, p. 703-723.

Research output: Contribution to journalReview article

Parsons, RF, Vivek, K, Redfield, RR, Migone, TS, Cancro, MP, Naji, A & Noorchashm, H 2009, 'B-cell tolerance in transplantation: Is repertoire remodeling the answer?', Expert Review of Clinical Immunology, vol. 5, no. 6, pp. 703-723. https://doi.org/10.1586/eci.09.63
Parsons, Ronald F. ; Vivek, Kumar ; Redfield, Robert R. ; Migone, Thi Sau ; Cancro, Michael P. ; Naji, Ali ; Noorchashm, Hooman. / B-cell tolerance in transplantation : Is repertoire remodeling the answer?. In: Expert Review of Clinical Immunology. 2009 ; Vol. 5, No. 6. pp. 703-723.
@article{46a26dc0d74f4be5afaa1e3735444c8d,
title = "B-cell tolerance in transplantation: Is repertoire remodeling the answer?",
abstract = "T lymphocytes are the primary targets of immunotherapy in clinical transplantation; however, B-lymphocytes and their secreted alloantibodies are also highly detrimental to the allograft. Therefore, the achievement of sustained organ transplant survival will likely require the induction of B-lymphocyte tolerance. During development, acquisition of B-cell tolerance to self-antigens relies on clonal deletion in the early stages of B-cell compartment ontogeny. We contend that this mechanism should be recapitulated in the setting of alloantigens and organ transplantation to eliminate the alloreactive B-cell subset from the recipient. Clinically feasible targets of B-cell-directed immunotherapy, such as CD20 and B-lymphocyte stimulator (BLyS), should drive upcoming clinical trials aimed at remodeling the recipient B-cell repertoire.",
keywords = "Allograft, B cell, BLyS, Homeostasis, Rejection, Selection, Tolerance",
author = "Parsons, {Ronald F.} and Kumar Vivek and Redfield, {Robert R.} and Migone, {Thi Sau} and Cancro, {Michael P.} and Ali Naji and Hooman Noorchashm",
year = "2009",
month = "11",
doi = "10.1586/eci.09.63",
language = "English (US)",
volume = "5",
pages = "703--723",
journal = "Expert Review of Clinical Immunology",
issn = "1744-666X",
publisher = "Expert Reviews Ltd.",
number = "6",

}

TY - JOUR

T1 - B-cell tolerance in transplantation

T2 - Is repertoire remodeling the answer?

AU - Parsons, Ronald F.

AU - Vivek, Kumar

AU - Redfield, Robert R.

AU - Migone, Thi Sau

AU - Cancro, Michael P.

AU - Naji, Ali

AU - Noorchashm, Hooman

PY - 2009/11

Y1 - 2009/11

N2 - T lymphocytes are the primary targets of immunotherapy in clinical transplantation; however, B-lymphocytes and their secreted alloantibodies are also highly detrimental to the allograft. Therefore, the achievement of sustained organ transplant survival will likely require the induction of B-lymphocyte tolerance. During development, acquisition of B-cell tolerance to self-antigens relies on clonal deletion in the early stages of B-cell compartment ontogeny. We contend that this mechanism should be recapitulated in the setting of alloantigens and organ transplantation to eliminate the alloreactive B-cell subset from the recipient. Clinically feasible targets of B-cell-directed immunotherapy, such as CD20 and B-lymphocyte stimulator (BLyS), should drive upcoming clinical trials aimed at remodeling the recipient B-cell repertoire.

AB - T lymphocytes are the primary targets of immunotherapy in clinical transplantation; however, B-lymphocytes and their secreted alloantibodies are also highly detrimental to the allograft. Therefore, the achievement of sustained organ transplant survival will likely require the induction of B-lymphocyte tolerance. During development, acquisition of B-cell tolerance to self-antigens relies on clonal deletion in the early stages of B-cell compartment ontogeny. We contend that this mechanism should be recapitulated in the setting of alloantigens and organ transplantation to eliminate the alloreactive B-cell subset from the recipient. Clinically feasible targets of B-cell-directed immunotherapy, such as CD20 and B-lymphocyte stimulator (BLyS), should drive upcoming clinical trials aimed at remodeling the recipient B-cell repertoire.

KW - Allograft

KW - B cell

KW - BLyS

KW - Homeostasis

KW - Rejection

KW - Selection

KW - Tolerance

UR - http://www.scopus.com/inward/record.url?scp=77949798194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949798194&partnerID=8YFLogxK

U2 - 10.1586/eci.09.63

DO - 10.1586/eci.09.63

M3 - Review article

AN - SCOPUS:77949798194

VL - 5

SP - 703

EP - 723

JO - Expert Review of Clinical Immunology

JF - Expert Review of Clinical Immunology

SN - 1744-666X

IS - 6

ER -